116 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs … product candidates may cause undesirable side effects or have other properties impacting safety that could delay or prevent their regulatory approval
8-K
EX-99.1
QNRX
Quoin Pharmaceuticals Ltd
13 Mar 24
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
4:52pm
a number of clinical endpoints
Eligibility age for enrollment into both studies has been lowered to fourteen years and older
No safety concerns have … a favorable impression of QRX003 across multiple assessed metrics.
No safety concerns have been reported to date for any subject in either of Quoin’s studies
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:06pm
and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:04pm
health and safety, product quality and safety and employment and labor matters, except in each case of (i), (ii) and (iii) as could not have or reasonably
8-K
EX-10.1
1nb8ytne6wk9pnb gj
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
424B4
7bgbtcgh
6 Mar 24
Prospectus supplement with pricing info
5:07pm
424B3
8h1k5z97jqepns8h2oa5
4 Mar 24
Prospectus supplement
5:27pm
8-K
EX-99.1
vu0ltqet6o
18 Dec 23
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
5:29pm
424B3
avfa zaeiy4d
9 Nov 23
Prospectus supplement
5:15pm
8-K
EX-99.1
wlpo8ozljj
9 Nov 23
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
5:10pm
424B3
eyo3igsx4f2z
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
nre4a8
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
424B3
yrtsptf a8rumr
3 Aug 23
Prospectus supplement
4:51pm
8-K
EX-99.1
cv60y96mw0ax y5d0bl
2 Aug 23
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
5:01pm